Spotlight On... Novartis' troubled Alcon unit recalls eye drops for sterility, potency problems; Endo tanks on women's health sale; AZ sells rights to constipation drug; Denmark vies for EMA; and more...

Supreme Court

F. Michael Ball, the former Hospira CEO who last month took over the top spot at Novartis' ($NVS) troubled Alcon unit, already had plenty on his to-do list. The division's sales are way off, it's squeezing manufacturing costs and it's dealing with a recall in Japan. Now, Ball has another recall to contend with. More from FiercePharmaManufacturing

@FiercePharma: FDA swats down Teva's EpiPen copy, putting Mylan in cruise control. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Teva plots global rebrand as it prepares to join hands with Allergan's generics unit. Article | Follow @CarlyHFierce

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

> Endo's ($ENDP) shares tanked Monday on the news that it was selling its women's health division. Report

> The U.S. Supreme Court has declined to review a lower-court decision ordering a law firm to give $10 million in settlement proceeds from GlaxoSmithKline ($GSK) to a common benefit fund in centralized product liability suits over diabetes med Avandia. Report (sub. req.)

> A recent study published in JAMA Internal Medicine found that while Addyi, the "female Viagra" pill, does affect women's libido, it does so only modestly. Report

> AstraZeneca ($AZN) has sold European rights to opioid-induced constipation drug Moventig to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million. More

> Denmark is vying to be the new home of the European Medicines Agency (EMA) if Britons vote to leave the European Union in a June referendum. More

> French drugmaker Ipsen's full-year core operating income rose 23.8% to €322.5 million. Report

> Germany's Stada forecast a slight increase in adjusted profit this year despite its prediction that business will likely be subdued through March. Report

Medical Device News

@FierceMedDev: Walgreens plots emergency exit from partnership with Theranos: FT. More | Follow @FierceMedDev

@EmilyWFierce: UPDATED: Zepatier beats Harvoni, Sovaldi in hep C clinical-data safety showdown: Advera Health Analytics. FiercePharma story | Follow @EmilyWFierce

> German startup Retina Implant nabs $28M for latest tech to restore sight to the blind. News

> Scientists create digital 'magic wand' to improve at-home device cybersecurity. Story

> Voice box maker Atos Medical goes on the chopping block for €1 billion: WSJ. Article

Biotech News

@FierceBiotech: PTC: With no evidence of Duchenne MD efficacy, FDA barred regulators' doors to ataluren. Article | Follow @FierceBiotech

@JohnCFierce: Does Roche's IL-13 setback in PhIII signal similar trouble ahead for AstraZeneca? Story | Follow @JohnCFierce

@DamianFierce: Hillary Clinton: enemy of Gut Guy. Watch | Follow @DamianFierce

> Savara raises $20M to push its inhaled antibiotic into Phase III. News

> ProMetic raises $30 million. Item

> Ipsen bets up to $855M on Exelixis' once-failed cancer drug. Article

Pharma Manufacturing News

> Lupin plans to add plant in Japan. News

> Potentially tainted heparin from China uncovered by French regulators. Report

> CMO helps TxCell move forward with clinical supplies after pilot plant closed. Item

> Novartis' Alcon unit recalls eye drop vials over questionable sterility. Story

> New plant to be online in UAE by end of 2016. Article

Pharma Asia News

> Bayer incoming CEO highlights OTC challenges in China in three-way integration. More

> China FDA prioritizes innovative drugs as 2015 approvals dipped. Story

> China's Mindray gets shareholder nod for reduced management-led buyout. Report

> China FDA chief Bi updates press on quality crackdown. More

> South Korea approved more clinical trials in 2015. Article

Drug Delivery News

> Israel's PolyPid raises $22M for its extended-release antibiotic to prevent surgical site infections. Item

> Sweden's Redwood gets private placement for its sustained-release dry eye disease candidate. Story

> AstraZeneca funds 'robotic pill' company Rani Therapeutics in pursuit of oral biologics. Article

> J&J, ViiV tout trial showing their long-acting HIV-fighting injectables are comparable to daily pills. More

> U.K.-Netherlands startups join forces for robot-assisted gene delivery to the eye. Article

And Finally... Monsanto is benefitting from an addition to a chemical safety bill that could help shield it from legal liability for a toxic chemical. Report (sub. req.)

Suggested Articles

AstraZeneca has signed a $750 million deal to produce up to 300 million doses of Oxford University's COVID-19 vaccine by year's end.

Moderna is entering an important time, its CEO says. And the company is doing so with a new finance chief from Big Biotech.

A new NEJM study found taking hydroxychloroquine after COVID-19 exposure doesn't reduce the risk of an infection. But questions remain.